<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557750</url>
  </required_header>
  <id_info>
    <org_study_id>Comb Mod Hepatoblastoma SECI</org_study_id>
    <nct_id>NCT02557750</nct_id>
  </id_info>
  <brief_title>Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience</brief_title>
  <official_title>Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to retrospectively investigate the effect of combined modality
      treatment of pediatric hepatoblastoma and the factors affecting the prognosis in accordance
      with the experience at the pediatric oncology department at South Egypt Cancer Institute.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Hepatoblastoma (HB) is the most common malignant liver tumor in children, with an incidence
      of 0.7 to 1 per million children &lt;15 years of age. Till 1970s, surgery was the primary
      modality of treatment of HB. Unfortunately, up to 60% of the patients present in an
      unresectable stage. Later, the chemo- responsiveness of the tumor was demonstrated which led
      to the incorporation of adjuvant chemotherapy with cisplatinum and doxorubicin in the
      treatment of HB. International Society of Pediatric Oncology (SIOP) pioneered the concept of
      neoadjuvant chemotherapy in the management of HB.

      Patients &amp; Methods:

      In the period from 2002 January till 2016 January, retrieval &amp; analysis of the medical
      records of pediatric patients with hepatoblastoma will be made at the pediatric oncology
      department, South Egypt Cancer Institute which represents the largest referral center in
      Upper Egypt. After pathologic confirmation of the diagnosis, these data will be categorized
      according to patients' demographics, presenting features, laboratory studies, including tumor
      markers &amp; histologic subtype, radiographic evaluation, disease staging, treatment course
      given, and subsequent treatment outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years</time_frame>
    <description>Time from the date of initiation of treatment until death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years</time_frame>
    <description>Time from the date of initiation of treatment until disease progression, or death for any reason.</description>
  </primary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hepatoblastoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric cancer patients, those diagnosed with hepatoblastoma, in the period from 2002
        January till 2016 January, and received treatment at the pediatric oncology department,
        their medical records will be retrospectively reviewed for data collection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose age less than or equal to 18 years.

          -  Patients diagnosed with hepatoblastoma.

        Exclusion Criteria:

          -  Patients whose age more than 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M. Morsy, MD</last_name>
      <phone>+2 01003314522</phone>
      <email>ahmedmohammed7829@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M. Morsy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid M. Rezk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ameer M. Abuelgheet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Bu, M., D. Terrada, et al. (2006).</citation>
  </reference>
  <reference>
    <citation>Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993 Jan;11(1):96-9.</citation>
    <PMID>8380296</PMID>
  </reference>
  <reference>
    <citation>Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey--1974. J Pediatr Surg. 1975 Jun;10(3):329-37.</citation>
    <PMID>49416</PMID>
  </reference>
  <reference>
    <citation>Mann JR, Kasthuri N, Raafat F, Pincott JR, Parkes SE, Muir KR, Ingram LC, Cameron AH. Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol. 1990 Jul;4(3):276-89.</citation>
    <PMID>2374747</PMID>
  </reference>
  <reference>
    <citation>Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, Feusner J, Campbell JR, Lloyd DA, Cherlow J, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991 Dec;9(12):2167-76.</citation>
    <PMID>1720452</PMID>
  </reference>
  <reference>
    <citation>Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28.</citation>
    <PMID>11078495</PMID>
  </reference>
  <reference>
    <citation>Quinn JJ, Altman AJ, Robinson HT, Cooke RW, Hight DW, Foster JH. Adriamycin and cisplatin for hepatoblastoma. Cancer. 1985 Oct 15;56(8):1926-9.</citation>
    <PMID>2411381</PMID>
  </reference>
  <reference>
    <citation>von Schweinitz D, Byrd DJ, Hecker H, Weinel P, Bode U, BÃ¼rger D, Erttmann R, Harms D, Mildenberger H. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer. 1997 Jul;33(8):1243-9.</citation>
    <PMID>9301450</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohammed Morsy, MD</investigator_full_name>
    <investigator_title>Lecturer, Pediatric Oncology Department</investigator_title>
  </responsible_party>
  <keyword>Childhood Cancer</keyword>
  <keyword>Pediatric Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatoblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

